Early recognition of depression and anxiety mood disorders is crucial to ensure adherence to anti-TNF-alpha therapy in patients with IBD who might require it in the long term for disease management, according to Dolovich et al. [58]. This evidence concerns the gene TNF and depressive symptom measurement.